title: Genomewide association study of movement-related adverse antipsychotic effects.
abstract: BACKGROUND
  Understanding individual differences in the development of extrapyramidal side effects (EPS) as a response to antipsychotic therapy is essential to individualize treatment.
  
  
  METHODS
  We performed genomewide association studies to search for genetic susceptibility to EPS. Our sample consisted of 738 schizophrenia patients, genotyped for 492K single nucleotide polymorphisms (SNPs). We studied three quantitative measures of antipsychotic adverse drug reactions-the Simpson-Angus Scale (SAS) for Parkinsonism, the Barnes Akathisia Rating Scale, and the Abnormal Involuntary Movement Scale (AIMS)-as well as a clinical diagnosis of probable tardive dyskinesia.
  
  
  RESULTS
  Two SNPs for SAS, rs17022444 and rs2126709 with p = 1.2 x 10(-10) and p = 3.8 x 10(-7), respectively, and one for AIMS, rs7669317 with p = 7.7 x 10(-8), reached genomewide significance (Q value < .1). rs17022444 and rs7669317 were located in intergenic regions and rs2126709 was located in ZNF202 on 11q24. Fourteen additional signals were potentially interesting (Q value < .5). The ZNF202 is a transcriptional repressor controlling, among other genes, PLP1, which is the major protein in myelin. Mutations in PLP1 cause Pelizaeus-Merzbacher disease, which has Parkinsonism as an occurring symptom. Altered mRNA expression of PLP1 is associated with schizophrenia.
  
  
  CONCLUSIONS
  Although our findings require replication and validation, this study demonstrates the potential of genomewide association studies to discover genes and pathways that mediate adverse effects of antipsychotics.
authors.affiliation: Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298, USA. kaaberg@vcu.edu
authors.forename: Karolina
authors.initials: K
authors.lastname: Aberg
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Adkins
authors.forename: József
authors.initials: J
authors.lastname: Bukszár
authors.forename: Bradley T
authors.initials: BT
authors.lastname: Webb
authors.forename: Stanley N
authors.initials: SN
authors.lastname: Caroff
authors.forename: Del D
authors.initials: DD
authors.lastname: Miller
authors.forename: Jonathan
authors.initials: J
authors.lastname: Sebat
authors.forename: Scott
authors.initials: S
authors.lastname: Stroup
authors.forename: Ayman H
authors.initials: AH
authors.lastname: Fanous
authors.forename: Vladimir I
authors.initials: VI
authors.lastname: Vladimirov
authors.forename: Joseph L
authors.initials: JL
authors.lastname: McClay
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Lieberman
authors.forename: Patrick F
authors.initials: PF
authors.lastname: Sullivan
authors.forename: Edwin J C G
authors.initials: EJ
authors.lastname: van den Oord
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D055106:Genome-Wide Association Study; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000209:etiology* / Q000235:genetics*; D018991:Myelin Proteolipid Protein / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011569:Psychiatric Status Rating Scales; D012333:RNA, Messenger / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics
chemical_list: D014150:Antipsychotic Agents; D018991:Myelin Proteolipid Protein; C472930:PLP1 protein, human; D012333:RNA, Messenger; D012097:Repressor Proteins; C115745:ZNF202 protein, human